| Date | Title | Description |
| 05.09.2024 | Connie R. Collingsworth joins Washington Research Foundation board of directors | Connie R. Collingsworth
Former COO and CLO of the Bill & Melinda Gates Foundation will provide strategic and operational leadership as member of foundation's board and finance committee
SEATTLE, Sept. 5, 2024 /PRNewswire-PRWeb/ -- Conni... |
| 04.08.2024 | Ocugen's $35 Million Offering: A Step Toward Innovation | Ocugen, Inc. is making waves in the biotechnology sector. The company recently closed a public offering, raising $35 million through the sale of 30,434,783 shares of common stock. Each share was priced at $1.15. This move is not just a fina... |
| 02.08.2024 | Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock | MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the closing of its prev... |
| 02.08.2024 | Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock | MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the closing of its prev... |
| 31.07.2024 | Ocugen, Inc. Announces Proposed Public Offering of Common Stock | MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has commenced a... |
| 31.07.2024 | Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock | MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its unde... |
| 03.06.2024 | OCGN DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN | NEW YORK, June 3, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Peri... |
| 24.05.2024 | ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN | NEW YORK, May 24, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Peri... |
| 13.03.2024 | Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 | - |
| 06.03.2024 | Ocugen to Present at Investing in Cures Summit | - |
| 24.05.2023 | Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock | - |
| 24.05.2023 | Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock | /EIN News/ -- MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announce... |
| 28.09.2022 | Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine | Japanese pharma Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint.
The drug, a protease inhibitor known as ensitrelvir, was administered daily for five days and... |
| 25.04.2022 | Updated: FDA warns small biotech Ocugen of potential $10K fines for failing to post trial results | The FDA is back to warning companies of $10,000 fines for failing to report the results of clinical trials, this time going after clinical stage biotech company Ocugen, known most recently for trying to bring a Covid-19 v... |
| 12.04.2022 | Manufacturing problems trigger another clinical hold for troubled Covid-19 vaccine — latest in a string of roadblocks | Just days after the World Health Organization suspended the use of Covaxin after a manufacturing site failed an inspection, the FDA has followed up with a clinical hold on the Covid-19 vaccine’s US co-developer.
Det... |
| 12.04.2022 | Abzena commits chunk of new $65M investment to build out in hot North Carolina scene | A San Diego CDMO has landed a $65 million investment to expand its drug substance and fill-finish manufacturing capacity, and it’s putting some of the money into its newest site on the other side of the country.
Abzena wi... |
| 25.03.2022 | Roger Perlmutter lures Roy Baynes away from Merck; Now, Voyager: Al Sandrock becomes a CEO after break from Biogen | Roy Baynes
→ Professional sports teams cycle through free agency every year, and core veterans from championship clubs routinely splinter off in different directions. In a similar vein, Merck in particular has seen widespread turnover with ... |
| 22.02.2022 | Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock | MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vacci... |
| 03.11.2021 | Ocugen Statement Regarding WHO Emergency Use Listing Announcement | Ocugen Statement Regarding WHO Emergency Use Listing Announcement
November 3, 2021
Malvern, Pa., - November 3, 2021 - We are pleased that WHO has recognized the potential value of COVAXIN™ (BBV152), a differentiated broad- spectrum vaccine ... |
| 07.05.2021 | OCUGEN, INC.
Ocugen Provides Business Update and First Quarter 2021 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency ... |
| 18.03.2021 | OCUGEN, INC.
Ocugen Provides Business Update and Full Year 2020 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET
COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim resultsEmergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™E... |
| 10.02.2021 | Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock | MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COV... |
| 30.09.2019 | Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing | Partnership to develop OCU400, Ocugen’s orphan drug designated gene therapy candidate in its modifier gene therapy platform
MALVERN, Pa, & TIANJIN, China–(BUSINESS WIRE)–September 30, 2019–
Ocugen, Inc., (NASDAQ: OCGN), a clinical stage... |
| 15.02.2018 | Funding news about Ocugen | According to documents filed with the SEC, Ocugen, Inc. — based in Malvern, Pa. — launched a new round of equity and debt financing on Feb. 1.
The company intends to raise as much as $5,000,000 and reports having raised the full amount. The... |
| 15.06.2017 | Ocugen Closes $7.5 Million Series B Financing | Ocugen, Inc., a biopharmaceutical company developing treatments for sight-threatening diseases, today announced it has closed a $7.5 million round of Series B funding. The round was co-led by Abdi Ibrahim, the leading Turkish pharmaceutical... |
| 15.06.2017 | Ocugen Closes $7.5M Series B Funding | Ocugen, a Malvern, PA-based clinical stage biopharmaceutical company developing treatments for sight-threatening diseases, closed a $7.5m round of Series B funding.
The round was co-led by Abdi Ibrahim, and the JSC Lancaster Group, with par... |
| 15.06.2017 | Term Sheet — Thursday, June 15 | GREEDY BASTARDS
Good morning.
Paid Content What you need to know about growing cyberattacks From ExtraHop
• That price would be more than double Slack’s latest private valuation from 2016.
• Amazon is not known for its monster acquisitions.... |
| 16.12.2016 | Ocugen Closes $6m Series A Funding | Ocugen, Inc., an Aurora, CO- and Malvern, PA-based biopharmaceutical company developing treatments for sight-threatening diseases, closed a $6m Series A funding.
Backers included $1m in funds raised through EB5 Life Sciences and Dr. Bernhar... |
| 15.12.2016 | Ocugen Secures $6M Series A Funding |
AURORA, CO, Ocugen, a biopharmaceutical company developing treatments for sight-threatening diseases, today announced that it has closed a $6 million round of Series A funding.
>> Click here for more funding data on Ocugen
>>... |
| 15.12.2016 | Ocugen Raises $6M Series A | Ocugen, Inc., a biopharmaceutical company developing treatments for sight-threatening diseases, today announced that it has closed a $6 million round of Series A funding, including $1 million in funds raised through EB5 Life Sciences LP. A ... |
| - | See the 17 fastest-growing biotech and pharma companies that hired thousands of new workers or grew at least 150% | Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider analyzed almost 500 SEC reports to find the fastest-growing drug companies right now.
We found 17 companies that grew their... |
| - | What to watch today: Wall Street edged higher after two-session tech rebound | U.S. stock futures rose Wednesday after another hot but expected inflation report. The Nasdaq on Tuesday rallied for the second session as tech stocks continued to rebound. The index gained 1.4% as bond yields stabilized, taking some pressu... |
| - | Insider identified 13 drug companies that are in a dangerous financial position and struggling to survive through 2022 | Mark Foley, CEO of Revance Therapeutics, Cameron Durrant, CEO of Humanigen, Nick Leschly Former CEO of Bluebird Bio, and Henry Ji, CEO of Sorrento Therapeutics, Revance Therapeutics; Humanigen; Sorrento Therapeutics; Wendy Maeda/Getty Image... |
